Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
besigliptin
- Development stage
- Phase 2
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Besigliptin (SHR117887) is an orally bioavailable, selective small molecule inhibitor of dipeptidyl peptidase-4 (DPP-4), developed by Jiangsu HengRui Medicine. It is designed for the treatment of type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, besigliptin slows the degradation of incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This preservation of incretins enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon secretion from alpha cells, leading to improved glycemic control. The drug has been evaluated in clinical trials both as a monotherapy and in combination with other anti-diabetic medications like metformin.
- Brand names
- Bisegliptin
- Other names
- besigliptin
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on besigliptin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on besigliptin.